Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1055-63. doi: 10.1016/j.ijrobp.2009.12.009. Epub 2010 May 17.

Management of inflammatory breast cancer after neoadjuvant chemotherapy.

Author information

1
Department of Radiation Oncology, Institut Curie, Paris, France.

Abstract

PURPOSE:

To assess the benefit of breast surgery for inflammatory breast cancer (IBC).

METHODS AND MATERIALS:

This retrospective series was based on 232 patients treated for IBC. All patients received primary chemotherapy followed by either exclusive radiotherapy (118 patients; 51%) or surgery with or without radiotherapy (114 patients; 49%). The median follow-up was 11 years.

RESULTS:

The two groups were comparable apart from fewer tumors <70 mm (43% vs. 33%, p = 0.003), a higher rate of clinical stage N2 (15% vs. 5%, p = 0.04), and fewer histopathologic Grade 3 tumors (46% vs. 61%, p <0.05) in the no-surgery group. The addition of surgery was associated with a significant improvement in locoregional disease control (p = 0.04) at 10 years locoregional free interval 78% vs. 59% but with no significant difference in overall survival rates or disease-free intervals. Late toxicities were not significantly different between the two treatment groups except for a higher rate of fibrosis in the no-surgery group (p <0.0001) and more lymphedema in the surgery group (p = 0.002).

CONCLUSION:

Our data suggest an improvement in locoregional control in patients treated by surgery, in conjunction with chemotherapy and radiotherapy, for IBC. Efforts must be made to improve overall survival.

PMID:
20478662
DOI:
10.1016/j.ijrobp.2009.12.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center